Literature DB >> 3030762

The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients.

K R Lees, J L Reid.   

Abstract

We have studied the effects of treatment for one month with perindopril, 4 or 8 mg once daily, in seven hypertensive patients. Blood pressure was lowered from 164/93 mm Hg to 145/84 mm Hg by 4 mg of perindopril and after one month remained at 142/82 mm Hg. Neither postural hypotension nor tachycardia occurred. Inhibition of plasma angiotensin converting enzyme (ACE) lasting for over 24 h was achieved and there was a significant increase in plasma renin activity (PRA). Maximum plasma concentrations of the active metabolite of perindopril, S-9780, were detected four h after oral administration. After treatment for one month there was evidence of reduced sensitivity of plasma ACE to the action of the inhibitor. The plasma concentration of S-9780 required to produce 50% inhibition of plasma ACE rose from 2.4 ng X ml-1 following the first dose to 5.5 ng X ml-1 after one month.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030762     DOI: 10.1007/BF00606623

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Effect on aging on plasma renin and aldosterone in normal man.

Authors:  P Weidmann; S De Myttenaere-Bursztein; M H Maxwell; J de Lima
Journal:  Kidney Int       Date:  1975-11       Impact factor: 10.612

2.  A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum.

Authors:  S G Chiknas
Journal:  Clin Chem       Date:  1979-07       Impact factor: 8.327

3.  Comparison of the actions of the angiotensin-converting enzyme inhibitors enalapril and S-9490-3 in sodium-deplete and sodium-replete spontaneously hypertensive rats.

Authors:  R DiNicolantonio; A E Doyle
Journal:  J Cardiovasc Pharmacol       Date:  1985 Sep-Oct       Impact factor: 3.105

4.  Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity.

Authors:  J K McKenzie; J A Clements
Journal:  J Clin Endocrinol Metab       Date:  1974-04       Impact factor: 5.958

5.  The physiological disposition and metabolism of enalapril maleate in laboratory animals.

Authors:  D J Tocco; F A deLuna; A E Duncan; T C Vassil; E H Ulm
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

6.  Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.

Authors:  M Laubie; P Schiavi; M Vincent; H Schmitt
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

7.  Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme.

Authors:  D B Case; J M Wallace; H J Keim; M A Weber; J E Sealey; J H Laragh
Journal:  N Engl J Med       Date:  1977-03-24       Impact factor: 91.245

8.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

9.  Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.

Authors:  B Waeber; H R Brunner; D B Brunner; A L Curtet; G A Turini; H Gavras
Journal:  Hypertension       Date:  1980 Mar-Apr       Impact factor: 10.190

10.  Heart rate control in hypertensive patients treated by captopril.

Authors:  A Sturani; C Chiarini; E Degliesposti; A Santoro; A Zuccalà; P Zucchelli
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

View more
  10 in total

1.  The effect of perindopril and hydrochlorothiazide alone and in combination on blood pressure and on the renin-angiotensin system in hypertensive subjects.

Authors:  C L Brown; C I Backhouse; J C Grippat; J P Santoni
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  The pharmacokinetics of perindopril in patients with liver cirrhosis.

Authors:  M Thiollet; C Funck-Brentano; J D Grangé; M Midavaine; G Resplandy; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 4.  Vascular haemodynamic effects of perindopril in essential hypertension.

Authors:  W Littler
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 5.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 6.  First-line treatment in hypertension. Role of perindopril.

Authors:  A Zanchetti
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of the newer ACE inhibitors. A review.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 8.  Perindopril. A review of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  P A Todd; A Fitton
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

9.  The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis.

Authors:  H H Tsai; K R Lees; C W Howden; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

10.  The pharmacokinetics of perindopril and its effects on serum angiotensin converting enzyme activity in hypertensive patients with chronic renal failure.

Authors:  J Sennesael; A Ali; P Sweny; M Vandenburg; D Slovic; M Dratwa; G Resplandy; P Genissel; P Desche
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.